| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2015-06-19 |
| タイトル |
|
|
タイトル |
Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease |
|
言語 |
en |
| タイトル |
|
|
タイトル |
clinically amyopathic dermatomyositis の有用な予後予測因子としての血清 IL-6 値 |
|
言語 |
ja |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
dermatomyositis |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
interstitial lung disease |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
anti-CADM140 antibody |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
interleukin-6 |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
prognostic factor |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
NARA, Mizuho
KOMATSUDA, Atsushi
OMOKAWA, Ayumi
TOGASHI, Masaru
OKUYAMA, Shin
SAWADA, Ken-ichi
WAKUI, Hideki
奈良, 瑞穂
小松田, 敦
面川, 歩
富樫, 賢
澤田, 賢一
涌井, 秀樹
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives Clinically amyopathic dermatomyositis (CADM) is considered as the subtype of dermatomyositis with amyopathy or hypomyopathy. Rapidly progressive interstitial lung disease (RP-ILD) is treatment-resistant and life-threatening in patients with CADM. Since useful markers for early diagnosis are necessary for early treatment in CADM patients with RP-IPD, this study aimed to investigate the differences of clinical and laboratory characteristics between alive patients (group A) and patients who died (group D). Methods Eleven patients with CADM complicating with RP-ILD were enrolled. Clinical manifestations and laboratory data before treatment were compared between group A and group D. Results Among them, six were alive and five died after treatment for RP-ILD. Serum IL-6 levels in group D were significantly higher than those in group A (median 19.7 vs 7.15 pg/ml; P=0.008). The stepwise regression analysis showed that IL-6 was the only prognostic factor significantly (p=0.035). Kaplan-Meier estimates showed that patient survivals were better in patients with IL-6 < 9pg/ml than those with > 9pg/ml (p=0.039). Other laboratory data were not different statistically between two groups. Conclusions Serum IL-6 may predict the prognosis of patients with CADM having RP-ILD. Patients with IL-6 >9pg/ml should be treated by the more aggressive immunosuppressive therapy. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
秋田大学審査学位論文の著者稿 |
|
言語 |
ja |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 書誌情報 |
en : Modern Rheumatology
巻 4,
p. 633-636,
発行日 2014-07-01
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
14397595 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA1157187X |
| 出版者 |
|
|
出版者 |
Informa Healthcare |
|
言語 |
en |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.3109/14397595.2013.844390 |
| 権利者情報 |
|
|
|
権利者名 |
日本リウマチ学会 |
ihakuikou1126.pdf (983.9 kB)
